Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma

Cancer Cell

Volumn 21, Issue 3, 2012, Pages 418-429

  Provenzano, Paolo P ^a   Cuevas, Carlos ^b   Chang, Amy E ^a   Goel, Vikas K ^a   Von Hoff, Daniel D ^c   Hingorani, Sunil R ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; HYALURONIC ACID;

ANIMAL CELL; ARTICLE; CANCER SURVIVAL; COLLAPSE; CONTROLLED STUDY; DIFFUSION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; MICROVASCULATURE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS PERFUSION; PRIORITY JOURNAL; PROTEIN TARGETING; STROMA CELL; THERMODYNAMICS; TISSUE PRESSURE; TUMOR MICROENVIRONMENT;

MURINAE;

EID: 84858602107     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2012.01.007     Document Type: Article

References (55)

1. Allison D.C., Piantadosi S., Hruban R.H., Dooley W.C., Fishman E.K., Yeo C.J., Lillemoe K.D., Pitt H.A., Lin P., Cameron J.L. DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma. J. Surg. Oncol. 1998, 67:151-159.
2. Balazs E.A., Denlinger J.L. Clinical uses of hyaluronan. Ciba Found. Symp. 1989, 143:265-275. discussion 275-280, 281-265.
3. Bissell M.J., Radisky D. Putting tumours in context. Nat. Rev. Cancer 2001, 1:46-54.
4. Boucher Y., Jain R.K. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res. 1992, 52:5110-5114.
5. Boucher Y., Kirkwood J.M., Opacic D., Desantis M., Jain R.K. Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res. 1991, 51:6691-6694.
6. Bouzin C., Feron O. Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery. Drug Resist. Updat. 2007, 10:109-120.
7. Brekken C., Hjelstuen M.H., Bruland O.S., de Lange Davies C. Hyaluronidase-induced periodic modulation of the interstitial fluid pressure increases selective antibody uptake in human osteosarcoma xenografts. Anticancer Res. 2000, 20(5B):3513-3519.
8. Burris H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., Cripps M.C., Portenoy R.K., Storniolo A.M., Tarassoff P., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997, 15:2403-2413.
9. Casper E.S., Green M.R., Kelsen D.P., Heelan R.T., Brown T.D., Flombaum C.D., Trochanowski B., Tarassoff P.G. Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest. New Drugs 1994, 12:29-34.
10. Conroy T., Desseigne F., Ychou M., Bouché O., Guimbaud R., Bécouarn Y., Adenis A., Raoul J.L., Gourgou-Bourgade S., de la Fouchardière C., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 2011, 364:1817-1825. Groupe Tumeurs Digestives of Unicancer, PRODIGE IntergroupPRODIGE Intergroup.
11. Curti B.D., Urba W.J., Alvord W.G., Janik J.E., Smith J.W., Madara K., Longo D.L. Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients: changes during treatment. Cancer Res. 1993, 53(10, Suppl):2204-2207.
12. Dangi-Garimella S., Krantz S.B., Barron M.R., Shields M.A., Heiferman M.J., Grippo P.J., Bentrem D.J., Munshi H.G. Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2. Cancer Res. 2011, 71:1019-1028.
13. Eikenes L., Bruland O.S., Brekken C., Davies Cde.L. Collagenase increases the transcapillary pressure gradient and improves the uptake and distribution of monoclonal antibodies in human osteosarcoma xenografts. Cancer Res. 2004, 64:4768-4773.
14. Eikenes L., Tari M., Tufto I., Bruland O.S., de Lange Davies C. Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx) in human osteosarcoma xenografts. Br. J. Cancer 2005, 93:81-88.
15. Farnell M.B., Pearson R.K., Sarr M.G., DiMagno E.P., Burgart L.J., Dahl T.R., Foster N., Sargent D.J. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 2005, 138:618-628. Pancreas Cancer Working Group, discussion 628-630.
16. Heldin C.H., Rubin K., Pietras K., Ostman A. High interstitial fluid pressure: an obstacle in cancer therapy. Nat. Rev. Cancer 2004, 4:806-813.
17. Hertel L.W., Boder G.B., Kroin J.S., Rinzel S.M., Poore G.A., Todd G.C., Grindey G.B. Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). Cancer Res. 1990, 50:4417-4422.
18. Hidalgo M. Pancreatic cancer. N. Engl. J. Med. 2010, 362:1605-1617.
19. Hingorani S.R., Petricoin E.F., Maitra A., Rajapakse V., King C., Jacobetz M.A., Ross S., Conrads T.P., Veenstra T.D., Hitt B.A., et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003, 4:437-450.
20. Hingorani S.R., Wang L., Multani A.S., Combs C., Deramaudt T.B., Hruban R.H., Rustgi A.K., Chang S., Tuveson D.A. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005, 7:469-483.
21. Izeradjene K., Hingorani S.R. Targets, trials, and travails in pancreas cancer. J. Natl. Compr. Canc. Netw. 2007, 5:1042-1053.
22. Jacobson A., Salnikov A., Lammerts E., Roswall P., Sundberg C., Heldin P., Rubin K., Heldin N.E. Hyaluronan content in experimental carcinoma is not correlated to interstitial fluid pressure. Biochem. Biophys. Res. Commun. 2003, 305:1017-1023.
23. Jain R.K. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 1987, 6:559-593.
24. Jain R.K. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev. 1990, 9:253-266.
25. Janssen B.J., Leenders P.J., Smits J.F. Short-term and long-term blood pressure and heart rate variability in the mouse. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2000, 278:R215-R225.
26. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60:277-300.
27. Kedem O., Katchalsky A. Thermodynamic analysis of the permeability of biological membranes to non-electrolytes. Biochim. Biophys. Acta 1958, 27:229-246.
28. Kedem O., Katchalsky A. A physical interpretation of the phenomenological coefficients of membrane permeability. J. Gen. Physiol. 1961, 45:143-179.
29. Less J.R., Posner M.C., Boucher Y., Borochovitz D., Wolmark N., Jain R.K. Interstitial hypertension in human breast and colorectal tumors. Cancer Res. 1992, 52:6371-6374.
30. Mattson D.L. Long-term measurement of arterial blood pressure in conscious mice. Am. J. Physiol. 1998, 274:R564-R570.
31. Michel C.C. Fluid movements through capillary walls. Handbook of Physiology, Section 2, Vol. IV, Microcirculation 1984, 375-409. American Physiological Society, Washington, D.C. E.M. Renkin, C.C. Michel (Eds.).
32. Moore M.J., Goldstein D., Hamm J., Figer A., Hecht J.R., Gallinger S., Au H.J., Murawa P., Walde D., Wolff R.A., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2007, 25:1960-1966. National Cancer Institute of Canada Clinical Trials Group.
33. Netti P.A., Hamberg L.M., Babich J.W., Kierstead D., Graham W., Hunter G.J., Wolf G.L., Fischman A., Boucher Y., Jain R.K. Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc. Natl. Acad. Sci. USA 1999, 96:3137-3142.
34. Netti P.A., Berk D.A., Swartz M.A., Grodzinsky A.J., Jain R.K. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 2000, 60:2497-2503.
35. Nieto J., Grossbard M.L., Kozuch P. Metastatic pancreatic cancer 2008: is the glass less empty?. Oncologist 2008, 13:562-576.
36. Oettle H., Post S., Neuhaus P., Gellert K., Langrehr J., Ridwelski K., Schramm H., Fahlke J., Zuelke C., Burkart C., et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007, 297:267-277.
37. Ogston A.G., Michel C.C. General descriptions of passive transport of neutral solute and solvent through membranes. Prog. Biophys. Mol. Biol. 1978, 34:197-217.
38. Olive K.P., Jacobetz M.A., Davidson C.J., Gopinathan A., McIntyre D., Honess D., Madhu B., Goldgraben M.A., Caldwell M.E., Allard D., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324:1457-1461.
39. Ozerdem U., Hargens A.R. A simple method for measuring interstitial fluid pressure in cancer tissues. Microvasc. Res. 2005, 70:116-120.
40. Provenzano P.P., Eliceiri K.W., Campbell J.M., Inman D.R., White J.G., Keely P.J. Collagen reorganization at the tumor-stromal interface facilitates local invasion. BMC Med. 2006, 4:38.
41. Ramanujan S., Pluen A., McKee T.D., Brown E.B., Boucher Y., Jain R.K. Diffusion and convection in collagen gels: implications for transport in the tumor interstitium. Biophys. J. 2002, 83:1650-1660.
42. Reed R.K., Rubin K., Wiig H., Rodt S.A. Blockade of beta 1-integrins in skin causes edema through lowering of interstitial fluid pressure. Circ. Res. 1992, 71:978-983.
43. Schultz R.M., Merriman R.L., Toth J.E., Zimmermann J.E., Hertel L.W., Andis S.L., Dudley D.E., Rutherford P.G., Tanzer L.R., Grindey G.B. Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts. Oncol. Res. 1993, 5:223-228.
44. Sherwood L. Human Physiology from Cells to Systems 1997, Wadsworth Publishing Company, Florence, KY. Third Edition.
45. Starling E.H. On the absorption of fluids from the connective tissue spaces. J. Physiol. 1896, 19:312-326.
46. Staverman A.J. Non-equilibrium thermodynamics of membrane processes. Trans. Faraday Soc. 1952, 48:176-185. 10.1039/TF9524800176.
47. Tempero M., Plunkett W., Ruiz Van Haperen V., Hainsworth J., Hochster H., Lenzi R., Abbruzzese J. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J. Clin. Oncol. 2003, 21:3402-3408.
48. Thompson C.B., Shepard H.M., O'Connor P.M., Kadhim S., Jiang P., Osgood R.J., Bookbinder L.H., Li X., Sugarman B.J., Connor R.J., et al. Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. Mol. Cancer Ther. 2010, 9:3052-3064.
49. Toole B.P. Hyaluronan: from extracellular glue to pericellular cue. Nat. Rev. Cancer 2004, 4:528-539.
50. Toole B.P., Slomiany M.G. Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells. Semin. Cancer Biol. 2008, 18:244-250.
51. Trédan O., Galmarini C.M., Patel K., Tannock I.F. Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst. 2007, 99:1441-1454.
52. Ueno H., Kiyosawa K., Kaniwa N. Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?. Br. J. Cancer 2007, 97:145-151.
53. Von Hoff D.D., Ramanathan R.K., Borad M.J., Laheru D.A., Smith L.S., Wood T.E., Korn R.L., Desai N., Trieu V., Iglesias J.L., et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J. Clin. Oncol. 2011, 29:4548-4554.
54. Wang W., Wyckoff J.B., Frohlich V.C., Oleynikov Y., Hüttelmaier S., Zavadil J., Cermak L., Bottinger E.P., Singer R.H., White J.G., et al. Single cell behavior in metastatic primary mammary tumors correlated with gene expression patterns revealed by molecular profiling. Cancer Res. 2002, 62:6278-6288.
55. Zhang L., Underhill C.B., Chen L. Hyaluronan on the surface of tumor cells is correlated with metastatic behavior. Cancer Res. 1995, 55:428-433.